| 2026-11-01in 68 d | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | BMYBristol-Myers Squibb | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | Recruiting |
| 2026-11-01in 68 d | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | CRBPCorbus Pharmaceuticals Inc. | Phase 1/2 | Solid Tumors | Recruiting |
| 2026-11-01in 68 d | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | ERASErasca, Inc. | Phase 1/2 | Solid Tumors | Active, not recruiting |
| 2026-11-01in 68 d | ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System | EWEdwards Lifesciences | Not applicable | Heart Failure | Active, not recruiting |
| 2026-11-01in 68 d | Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab | SRRKScholar Rock, Inc. | Phase 3 | Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin | Active, not recruiting |
| 2026-11-02in 69 d | A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | AZNAstraZeneca | Phase 3 | Cutaneous Lupus Erythematosus | Active, not recruiting |
| 2026-11-02in 69 d | OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis | AZNAstraZeneca | — | ATTR Amyloidosis | Recruiting |
| 2026-11-02in 69 d | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) | BMYBristol-Myers Squibb | Phase 3 | Bipolar Disorder Type I With Mania or Mania With Mixed Features | Recruiting |
| 2026-11-02in 69 d | Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi Arabia | DXCMDexCom, Inc. | Phase 4 | Type 2 Diabetes on Insulin | Active, not recruiting |
| 2026-11-02in 69 d | A Retrospective Real-World Cohort Study | NVONovo Nordisk A/S | — | Obesity | Not yet recruiting |
| 2026-11-02in 69 d | A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma | REGNRegeneron Pharmaceuticals | Phase 2 | Melanoma | Active, not recruiting |
| 2026-11-04in 71 d | A Trial of Lu AH69593 in Healthy Participants | HLUN-B.COH. Lundbeck A/S | Phase 1 | Healthy Participants | Not yet recruiting |
| 2026-11-05in 72 d | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | INCYIncyte Corporation | Phase 2 | B-Cell Malignancies | Active, not recruiting |
| 2026-11-05in 72 d | Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next) | REGNRegeneron Pharmaceuticals | — | Retinopathy of Prematurity | Active, not recruiting |
| 2026-11-06in 73 d | Safety and Efficacy of Xalkori ROS1 | PFEPfizer | — | Lung Cancer | Active, not recruiting |
| 2026-11-06in 73 d | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps | SNYSanofi | Phase 3 | Chronic Rhinosinusitis | Active, not recruiting |
| 2026-11-11in 78 d | Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | AZNAstraZeneca | Phase 3 | Breast Cancer; HER2-positive; Metastatic | Active, not recruiting |
| 2026-11-11in 78 d | GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort | AZNAstraZeneca | — | Gynaecological Cancers | Recruiting |
| 2026-11-11in 78 d | A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment | AZNAstraZeneca | Phase 1 | Moderate Hepatic Impairment | Recruiting |
| 2026-11-11in 78 d | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | PGENPrecigen, Inc | Phase 2 | Cervical Cancer | Recruiting |
| 2026-11-12in 79 d | A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants | 4523.TEisai Inc. | Phase 1 | Healthy Volunteers | Not yet recruiting |
| 2026-11-13in 80 d | Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset | PFEPfizer | — | Respiratory Syncytial Virus | Not yet recruiting |
| 2026-11-13in 80 d | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | REGNRegeneron Pharmaceuticals | Phase 1/2 | Solid Tumors | Active, not recruiting |
| 2026-11-13in 80 d | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | REGNRegeneron Pharmaceuticals | Phase 2 | Obesity | Active, not recruiting |
| 2026-11-15in 82 d | Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes | ACHVAchieve Life Sciences | Phase 3 | Vaping Cessation | Not yet recruiting |
| 2026-11-15in 82 d | A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus | AMGNAmgen | Phase 1 | Type 2 Diabetes | Active, not recruiting |
| 2026-11-15in 82 d | National Acalabrutinib Observational Study | AZNAstraZeneca | — | Chronic Lymphocytic Leukemia | Active, not recruiting |
| 2026-11-15in 82 d | A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC) | PFEPfizer | — | Prostate Cancer | Not yet recruiting |
| 2026-11-17in 84 d | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | AZNAstraZeneca | Phase 2 | Gastric Cancer | Recruiting |
| 2026-11-17in 84 d | A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants. | BMYBristol-Myers Squibb | Phase 1 | Healthy Volunteers | Recruiting |
| 2026-11-17in 84 d | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | SOBI.STSwedish Orphan Biovitrum | Phase 4 | Hemophilia A | Active, not recruiting |
| 2026-11-18in 85 d | Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity | AMGNAmgen | Phase 1 | Overweight | Active, not recruiting |
| 2026-11-18in 85 d | A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | AZNAstraZeneca | Phase 1 | Healthy Participants | Recruiting |
| 2026-11-18in 85 d | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | BMYBristol-Myers Squibb | Phase 3 | Sjögren's Syndrome | Active, not recruiting |
| 2026-11-18in 85 d | Efficacy and Safety of NVX-CoV2705 | NVAXNovavax | Phase 4 | COVID-19 | Active, not recruiting |
| 2026-11-18in 85 d | A Study of SPY003-207 in Healthy Volunteers | SYRESpyre Therapeutics, Inc. | Phase 1 | Healthy | Active, not recruiting |
| 2026-11-19in 86 d | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants | VRTXVertex Pharmaceuticals Incorporated | Phase 1 | Cystic Fibrosis | Recruiting |
| 2026-11-20in 87 d | Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism | BLCOBausch & Lomb Incorporated | Not applicable | Hyperopia | Active, not recruiting |
| 2026-11-20in 87 d | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | INCYIncyte Corporation | Phase 2 | Asthma | Active, not recruiting |
| 2026-11-20in 87 d | A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach | NSPRInspireMD | Not applicable | Carotid Artery Diseases | Recruiting |
| 2026-11-20in 87 d | Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo | SKYESkye Bioscience, Inc. | Phase 2 | Obesity | Active, not recruiting |
| 2026-11-23in 90 d | Study of XB010 in Subjects With Solid Tumors | EXELExelixis | Phase 1 | Solid Tumors | Recruiting |
| 2026-11-24in 91 d | Study of AZD0754 in Participants With Metastatic Prostate Cancer | AZNAstraZeneca | Phase 1/2 | Prostate Cancer | Recruiting |
| 2026-11-24in 91 d | A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | TECXTectonic Therapeutic | Phase 2 | Heart Failure | Active, not recruiting |
| 2026-11-29in 96 d | Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service. | AZNAstraZeneca | — | Lung Cancer | Recruiting |
| 2026-11-29in 96 d | A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | PFEPfizer | Phase 3 | Menstrual Migraine | Recruiting |
| Nov 2026≤ 97 d | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series | 051910.KSLG Chem | Phase 2/3 | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type b | Recruiting |
| 2026-11-30in 97 d | Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants | 4523.TEisai Co., Ltd. | Phase 1 | Hepatic Impairment | Recruiting |
| Nov 2026≤ 97 d | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | ABBVAbbVie | Phase 2 | Chronic Lymphocytic Leukemia | Recruiting |
| Nov 2026≤ 97 d | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer | ABBVAbbVie | Phase 2 | Primary Peritoneal Cancer | Active, not recruiting |
| Nov 2026≤ 97 d | A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | ABBVAbbVie | — | Acute Myeloid Leukemia | Recruiting |
| Nov 2026≤ 97 d | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | ABBVAbbVie | Phase 2 | Hepatocellular Carcinoma | Active, not recruiting |
| Nov 2026≤ 97 d | An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan | ABBVAbbVie | — | Crohn's Disease | Recruiting |
| Nov 2026≤ 97 d | A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy | ABBVAbbVie | — | Acute Myeloid Leukemia | Active, not recruiting |
| Nov 2026≤ 97 d | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | ABBVAbbVie | Phase 2 | Generalized Anxiety Disorder (GAD) | Recruiting |
| Nov 2026≤ 97 d | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants | ABBVAbbVie | Phase 1 | Healthy Volunteer | Active, not recruiting |
| Nov 2026≤ 97 d | A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy | ABBVAbbVie | — | Ovarian Cancer | Recruiting |
| Nov 2026≤ 97 d | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | ALKSAlkermes, Inc. | Phase 2 | Idiopathic Hypersomnia | Recruiting |
| 2026-11-30in 97 d | A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | AMGNAmgen | Phase 1/2 | Advanced MTAP-null Solid Tumors | Active, not recruiting |
| Nov 2026≤ 97 d | Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective Endocarditis | ANGOAngiodynamics, Inc. | Not applicable | Infective Endocarditis (IE) | Not yet recruiting |
| Nov 2026≤ 97 d | A Study Evaluating APG777 in Atopic Dermatitis | APGEApogee Therapeutics, Inc. | Phase 2 | Atopic Dermatitis | Active, not recruiting |
| Nov 2026≤ 97 d | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | APTOFAptose Biosciences Inc. | Phase 1/2 | Acute Myeloid Leukemia | Recruiting |
| 2026-11-30in 97 d | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | ARVNArvinas Inc. | Phase 1/2 | KRAS G12D Mutation, Advanced Solid Cancer | Active, not recruiting |
| Nov 2026≤ 97 d | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | ATOSAtossa Therapeutics, Inc. | Phase 2 | Breast Cancer | Active, not recruiting |
| 2026-11-30in 97 d | Suprachoroidal Administration in Subjects With Metastases to the Choroid | AURAAura Biosciences | Phase 2 | Eye Cancer, Primary Cancer | Recruiting |
| 2026-11-30in 97 d | A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia | AZNAstraZeneca | — | NSCLC, Non-small-cell Lung Carcinoma | Active, not recruiting |
| 2026-11-30in 97 d | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | AZNAstraZeneca | Phase 2 | Hepatocellular Carcinoma | Active, not recruiting |
| 2026-11-30in 97 d | Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | AZNAstraZeneca | — | Asthma | Active, not recruiting |
| Nov 2026≤ 97 d | HemoSphere Alta Study | BDXBecton, Dickinson and Company | — | Hemodynamic Instability | Active, not recruiting |
| Nov 2026≤ 97 d | UK PureWick™ At-Home Pilot Study | BDXBecton, Dickinson and Company | — | Urinary Incontinence | Recruiting |
| 2026-11-30in 97 d | A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors | BIOABioAge Labs, Inc. | Phase 2 | Obesity | Recruiting |
| Nov 2026≤ 97 d | Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy | BLCOBausch & Lomb Incorporated | Not applicable | Myopia | Not yet recruiting |
| Nov 2026≤ 97 d | A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers | BLCOBausch & Lomb Incorporated | Phase 1 | Ocular Pain | Active, not recruiting |
| 2026-11-30in 97 d | A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy | BMYBristol-Myers Squibb | — | Hypertrophic Cardiomyopathy | Recruiting |
| Nov 2026≤ 97 d | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | BNTXBioNTech SE | Phase 2 | Colorectal Cancer | Active, not recruiting |
| Nov 2026≤ 97 d | A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV | BNTXBioNTech SE | Phase 1 | HIV | Recruiting |
| Nov 2026≤ 97 d | VTP-1000 in Adults With Celiac Disease | BRNSBarinthus Biotherapeutics | Early Phase 1 | Celiac Disease | Recruiting |
| Nov 2026≤ 97 d | Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass | BSXBoston Scientific Corporation | Not applicable | Weight Regain, Weight Loss | Recruiting |
| Nov 2026≤ 97 d | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | CAMX.STCamurus AB | Phase 3 | Gastro-enteropancreatic Neuroendocrine Tumor | Active, not recruiting |
| Nov 2026≤ 97 d | Surveillance HeartCare® Outcomes Registry | CDNACareDx | — | Heart Transplant Rejection | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | CGEMCullinan Therapeutics Inc. | Phase 1 | NHL, NHL, Relapsed, Adult | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | CGONCG Oncology, Inc. | Phase 3 | Bladder Cancer | Active, not recruiting |
| 2026-11-30in 97 d | A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate | CINPHA.STCinclus Pharma Holding AB | Phase 1 | Pharmacokinetics, Cardiodynamic ECG, Safety, and Tolerability, GERD | Recruiting |
| Nov 2026≤ 97 d | To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis. | CLColgate Palmolive | Phase 3 | Gingivitis | Active, not recruiting |
| Nov 2026≤ 97 d | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | CRDFCardiff Oncology | Phase 2 | Colorectal Cancer | Active, not recruiting |
| Nov 2026≤ 97 d | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | DBV.PADBV Technologies | Phase 3 | Allergy, Peanut Allergy | Active, not recruiting |
| Nov 2026≤ 97 d | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults | ENTAEnanta Pharmaceuticals, Inc | Phase 1 | Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | Recruiting |
| Nov 2026≤ 97 d | Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) | GILDGilead Sciences | Phase 1 | Weight Management | Recruiting |
| Nov 2026≤ 97 d | Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief | HLNHALEON | Not applicable | Dentin Sensitivity | Active, not recruiting |
| Nov 2026≤ 97 d | A Clinical Study to Assess the Effectiveness of Use of Three Experimental Denture Adhesives Compared to Using No-Adhesive | HLNHALEON | Not applicable | Denture Retention | Recruiting |
| Nov 2026≤ 97 d | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | IBRXImmunityBio, Inc. | Phase 2 | Non-muscle Invasive Bladder Cancer (NMIBC) | Not yet recruiting |
| 2026-11-30in 97 d | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers | IMCRImmunocore Ltd | Phase 1/2 | Cancer, HLA-A*02:01-positive | Recruiting |
| Nov 2026≤ 97 d | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | IMUXImmunic AG | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| Nov 2026≤ 97 d | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | IMUXImmunic AG | Phase 3 | Multiple Sclerosis | Active, not recruiting |
| Nov 2026≤ 97 d | Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema | KPRXKiora Pharmaceuticals, Inc. | Phase 2 | Macular Edema | Recruiting |
| Nov 2026≤ 97 d | A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease | KRYSKrystal Biotech, Inc. | Early Phase 1 | Hailey Hailey Disease, Skin Diseases, Lesion Skin | Recruiting |
| Nov 2026≤ 97 d | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | LLYEli Lilly and Company | Phase 3 | Obstructive Sleep Apnea | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | LLYEli Lilly and Company | Phase 3 | Obesity | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | LLYEli Lilly and Company | Phase 3 | Type 1 Diabetes | Active, not recruiting |
| Nov 2026≤ 97 d | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | LLYEli Lilly and Company | Phase 3 | Type 1 Diabetes | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of LY4064912 in Healthy Participants and With Overweight or Obesity | LLYEli Lilly and Company | Phase 1 | Obesity | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | LLYEli Lilly and Company | Phase 2 | Type 2 Diabetes | Active, not recruiting |
| Nov 2026≤ 97 d | A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | LLYEli Lilly and Company | Phase 1 | Type 2 Diabetes | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of LY4515100 in Participants With Pain Following Third Molar Removal | LLYEli Lilly and Company | Phase 2 | Acute Pain, Molar, Molar, Third, Surgery, Oral | Recruiting |
| Nov 2026≤ 97 d | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | MGNXMacroGenics | Phase 1 | Acute Myeloid Leukemia | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of MGC028 in Participants With Advanced Solid Tumors | MGNXMacroGenics | Phase 1 | Solid Tumors | Recruiting |
| 2026-11-30in 97 d | A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) | MRNAModernaTX, Inc. | Phase 1/2 | Glycogen Storage Disease | Active, not recruiting |
| Nov 2026≤ 97 d | Long-term Safety and Performance of CMF Porous Titanium Implants | MTLS.BRMaterialise | — | Craniofacial Defects | Not yet recruiting |
| 2026-11-30in 97 d | Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | NVONovo Nordisk A/S | — | Type 2 Diabetes | Enrolling by invitation |
| Nov 2026≤ 97 d | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | ONCBeOne Medicines | Phase 1/2 | Multiple Myeloma | Recruiting |
| Nov 2026≤ 97 d | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | ONCBeOne Medicines | Phase 1/2 | Follicular Lymphoma | Recruiting |
| Nov 2026≤ 97 d | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | ONCBeOne Medicines | Phase 2 | Chronic Lymphocytic Leukemia | Active, not recruiting |
| Nov 2026≤ 97 d | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | RCUSArcus Biosciences, Inc. | Phase 1 | Advanced Cancer | Active, not recruiting |
| 2026-11-30in 97 d | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | REPLReplimune, Inc. | Phase 1 | Solid Tumors | Active, not recruiting |
| 2026-11-30in 97 d | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | RNACCartesian Therapeutics | Phase 3 | Myasthaenia Gravis | Recruiting |
| 2026-11-30in 97 d | Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan | SNYSanofi | Phase 3 | Immune Thrombocytopenia | Active, not recruiting |
| 2026-11-30in 97 d | Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | SNYSanofi | — | Type 1 Diabetes | Recruiting |
| Nov 2026≤ 97 d | Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model | TRAWTraws Pharma, Inc. | Phase 2 | Influenza | Not yet recruiting |
| Nov 2026≤ 97 d | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | TYRATyra Biosciences, Inc | Phase 1/2 | Urothelial Carcinoma | Active, not recruiting |
| Nov 2026≤ 97 d | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | VIRVir Biotechnology, Inc. | Phase 2 | Viral Hepatitis | Active, not recruiting |
| Nov 2026≤ 97 d | Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience | VTRSViatris Inc. | Phase 4 | Healthy Non-dependent, Recreational Sedative Users | Recruiting |
| Nov 2026≤ 97 d | Embody Post-Market Clinical Follow-Up Study | ZBHZimmer Biomet | — | Tendon Injuries- Subscapularis | Active, not recruiting |
| Nov 2026≤ 97 d | Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense | ZURAZura Bio Inc | Phase 2 | Hidradenitis Suppurativa | Active, not recruiting |
